Internal Medicine Department, State Medical University, Zaporozhye, 69035, Ukraine.
Clinical Pharmacology Department, State Medical University, Zaporozhye, 69035, Ukraine.
Biomark Med. 2019 Jun;13(9):737-750. doi: 10.2217/bmm-2018-0449. Epub 2019 Jun 3.
: to evaluate the associations between signatures of apoptotic endothelial cell-derived microvesicles (MVs) with phenotypes of chronic heart failure (HF). The study cohort consisted of 388 prospectively involved subjects with HF patients with predominantly reduced left ventricular ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF) and HF with mid-range ejection fraction (HFmrEF). All biomarkers were measured at baseline. The number of circulating CD31/annexin V MVs in HFrEF and HFmrEF patients was similar. The number of circulating CD144/annexin V MVs in HFrEF patients was significantly higher than HFmrEF and HFpEF. We determined that a combination of number of circulating CD31/annexin V MVs and Gal-3 was the best predictor of HFpEF and that number of circulating CD144/annexin V MVs is able to increase predictive capabilities of soluble ST2 (sST2) and Gal-3 for HFrEF. We found that the number of circulating CD31/annexin V MVs may improve a predictive capacity for conventional HF biomarkers.
: 评估凋亡内皮细胞来源微泡 (MVs) 特征与慢性心力衰竭 (HF) 表型之间的相关性。研究队列包括 388 名前瞻性 HF 患者，主要为左心室射血分数降低的心力衰竭 (HFrEF)、射血分数保留的心力衰竭 (HFpEF) 和射血分数中间范围的心力衰竭 (HFmrEF)。所有生物标志物均在基线时测量。HFrEF 和 HFmrEF 患者循环中 CD31/膜联蛋白 V MVs 的数量相似。HFrEF 患者循环中 CD144/膜联蛋白 V MVs 的数量明显高于 HFmrEF 和 HFpEF。我们确定循环 CD31/膜联蛋白 V MVs 和 Gal-3 的数量的组合是 HFpEF 的最佳预测因子，而循环 CD144/膜联蛋白 V MVs 的数量能够提高可溶性 ST2 (sST2) 和 Gal-3 对 HFrEF 的预测能力。我们发现循环 CD31/膜联蛋白 V MVs 的数量可能会提高常规 HF 生物标志物的预测能力。
